Modality
siRNA
MOA
DLL3 ADC
Target
CGRP
Pathway
Wnt
CeliacMCL
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Mar 2026
Phase 2Current
NCT07814839
2,285 pts·Celiac
2018-01→2026-03·Recruiting
2,285 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-274d agoPh3 Readout· Celiac
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-03-27 · 4d ago
Celiac
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07814839 | Phase 2/3 | Celiac | Recruiting | 2285 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |